Migraine and multiple sclerosis: Epidemiology and approach to treatment
Authors:
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 2 (2) , 73-79
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- National Institute of Neurological Disorders and Stroke (K12NS001692)
- American Academy of Neurology
- National Multiple Sclerosis Society
- University of California, San Francisco
- National Institutes of Health
- Amgen
This publication has 77 references indexed in Scilit:
- Patients with migraine do not have MRI-visible cortical lesionsJournal of Neurology, 2012
- Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Migraine and motion sickness: What is the link?Progress in Neurobiology, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple SclerosisNew England Journal of Medicine, 2008
- Temporal trends in the incidence of multiple sclerosisNeurology, 2008
- Rate of Pregnancy-Related Relapse in Multiple SclerosisNew England Journal of Medicine, 1998
- Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosisBrain, 1997